0767 (0767) Fair Value & Analysis

Healthcare · Market cap HK$312M

0 0767 0767 · HK

PriceHK$0.4900

Fair ValueHK$0.2400

Upside-51.0%

Quality43/100

Evidence: Low Range HK$0.1600 – HK$0.3000

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price +28.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.3300 – HK$0.6500 · fair‑value band HK$0.1600 – HK$0.3000 · the HK$0.4900 price screens above the HK$0.2400 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0767 (0767) currently trades at HK$0.4900, while our model-based Fair Value estimate is HK$0.2400 — implying the stock looks roughly 51.0% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 0767 generated revenue of HK$126M at a net margin of -13.3%. Revenue declined 37.8% year over year. It earns a return on equity of -4.0%. The balance sheet holds a net cash position of HK$18.7M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$126M

Revenue growth (YoY) -37.8%

Net margin -13.3%

Return on equity -4.0%

Free cash flow −HK$23.1M FY2025

Operating margin -58.9%

More key figures

EPS (TTM) HK$-0.0400

EPS growth (YoY) -75.0%

Net cash HK$18.7M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0767 reported revenue of HK$165M in FY2025 versus HK$63.0M in FY2021, a compound +27.3%/yr. Reported net income was −HK$16.8M in FY2025.

Revenue +27.3%/yr

FY21 HK$63.0M

FY22 HK$89.4M

FY23 HK$65.0M

FY24 HK$169M

FY25 HK$165M

Net income

FY21 HK$6.1M

FY22 −HK$904K

FY23 HK$2.3M

FY24 −HK$34.7M

FY25 −HK$16.8M

Is 0767 fairly valued? → Check now

Similar stocks

6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$464.01	$326.81	-30%
Danaher Corporation DHR	$183.63	$87.65	-52%
WuXi AppTec Co WUXAY	$18.59	$25.09	+35%
IDEXX Laboratories, Inc IDXX	$562.16	$190.95	-66%
Lonza Group LZAGY	$61.97	$14.23	-77%
Agilent Technologies, Inc A	$131.62	$60.93	-54%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0767 (0767) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.2400 versus a price of HK$0.4900 — about −51% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0767?

Our model-based fair value for 0767 is HK$0.2400 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.4900.

What is the quality score of 0767?

0767 has a Quality Score of 43/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0767 (0767)?

0767 reported trailing-twelve-month revenue of about HK$126M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0767?

The net profit margin of 0767 is about -13.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.